Efficacy and toxicity of Trastuzumab at the maintaining dose of 1 mg/kg/week versus the standard dose of 2 mg/kg/week in combination with chemotherapy in metastatic breast cancer patients. A phase III multicenter study.
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2013
At a glance
- Drugs Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms GIM-7-DOT
- 28 Apr 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 27 Jul 2011 New trial record